IPM Take
Alzheimer’s treatment is moving out of the infusion chair. The risk is not.
The FDA approval of Leqembi Iqlik gives patients with early Alzheimer’s disease a once-weekly subcutaneous initiation option, reducing some of the burden of repeated intravenous infusions. That matters. Time in clinic is not a small inconvenience for patients, caregivers or health systems.
But convenience must not be mistaken for simplicity. Anti-amyloid treatment still depends on timely diagnosis, specialist assessment, MRI monitoring, risk counselling, caregiver readiness and a system capable of managing amyloid-related imaging abnormalities before they become harm.
The injection is shorter. The pathway is not.
Executive Summary
FDA has approved Leqembi Iqlik, lecanemab-irmb, as a once-weekly subcutaneous initiation dose for adults with early Alzheimer’s disease, including mild cognitive impairment or mild dementia due to Alzheimer’s disease.
The approved initiation dose is 500 mg once weekly, administered as two 250 mg injections, each taking around 15 seconds. After 18 months, treatment may continue using the previously approved once-weekly 360 mg subcutaneous maintenance dose or the intravenous maintenance regimen.
The approval is based on data from the Clarity AD open-label extension and subcutaneous substudies supporting comparable exposure to intravenous initiation dosing. The drug remains subject to serious safety warnings, including amyloid-related imaging abnormalities, or ARIA, which can be life-threatening in rare cases.
This is a meaningful implementation milestone. It does not remove the need for specialist care, monitoring infrastructure or careful patient selection.
Why it matters
- Patients / advocates: A shorter treatment visit can reduce burden, but patients still need honest counselling about benefit, risk and the monitoring required to use the medicine safely.
- Clinicians: Subcutaneous initiation may ease capacity pressure, but it does not eliminate the need for amyloid confirmation, MRI surveillance and ARIA management.
- Hospitals / providers: If anti-amyloid care moves closer to home, systems must decide who trains patients, who monitors safety and who responds when problems appear.
- Payers: Lower administration burden may change the economics of treatment delivery, but access will still depend on diagnostic capacity and coverage rules.
Alzheimer’s care has always been constrained by infrastructure.
A treatment can exist, a patient can be eligible, and a family can be ready, yet the pathway can still collapse under the weight of scans, specialist visits, infusion capacity and monitoring requirements. For anti-amyloid therapies, the system is not a background detail. It is part of the treatment.
Leqembi Iqlik changes one piece of that architecture.
A once-weekly subcutaneous initiation dose could reduce time in infusion centres and make treatment less disruptive for some patients and caregivers. That is not a cosmetic improvement. For families already navigating memory loss, transport, work schedules and anxiety around decline, fewer long clinic visits may matter.
But the politics of Alzheimer’s access will not be solved by a shorter injection.
Patients still need to be identified early enough. They still need biomarker confirmation. They still need MRI monitoring before and during treatment. They still need a clinician who can explain what ARIA is, who is at higher risk, and what symptoms require urgent attention. The treatment may be administered more easily, but the accountability around it remains complex.
That is where implementation will either become serious or performative.
A home-friendly formulation should not become an excuse to push risk onto families without building the support around them. It should be used to redesign Alzheimer’s care around earlier detection, better navigation and safer follow-up.
The injection takes seconds. The responsibility lasts much longer.
